The Latest Breaking News from PFE

Covid cases continue to get registered to date, and the Biden administration is attempting to allocate more funding to address the pandemic. While investors should consider buying quality COVID-19 stock Pfizer (PFE), we think Teladoc Health (TDOC) might be best avoided now, considering its weak fundamentals. Keep reading….

With festive spending keeping the economy resilient despite the threat of interest rate hikes, it could be wise to invest in Pfizer (PFE), Broadcom (AVGO), and Restaurants Brands International (QSR) to give your portfolios a touch of holiday spirit. Continue reading….

Amid prevalent COVID-19 cases, vaccine pioneer Pfizer (PFE) is significantly benefiting. Moreover, the company beat wall street expectations in the third quarter with a robust financial result and raised its revenue and EPS guidance for the year. Given its strong fundamentals, the stock could be a wise addition to your…

The pharmaceutical industry is rapidly evolving to meet today’s health challenges. The pharmaceutical industry's long-term prospects look bright with a globally aging population set to increase healthcare expenditure. Moreover, given the industry’s ability to stay resilient amid economic headwinds, it could be wise to invest in fundamentally strong pharmaceutical stocks…

As the Fed’s aggressive monetary policy resulted in slightly cooled inflation last month, investors are hopeful of smaller rate hikes ahead. However, since a recession is expected to hit the economy next year, we think fundamentally sound stocks Pfizer (PFE), Flowers Foods (FLO), and Xperi (XPER), which are rated Strong…

While market volatility is still prevalent, experts believe the U.S. economy might succeed in achieving a 'soft landing.' Moreover, most S&P 500 companies surpassed revenue and EPS estimates in the third quarter. Therefore, fundamentally sound stocks Pfizer (PFE) and Flowers Foods (FLO) could be ideal additions to your portfolio now.…

Although inflation eased slightly last month, the Fed has indicated that the final level of interest rates could be higher than expected. With further interest rate hikes and the possibility of a recession expected to keep the market under pressure, it could be wise to buy dividend-paying stocks Pfizer (PFE),…

Leading biopharmaceutical company Pfizer’s (PFE) third-quarter results demonstrated strength across most areas of its business. Moreover, the company raised its 2022 financial guidance for revenues and adjusted EPS. Also, the company has increased its dividend for 12 consecutive years, and its annual dividend yields more than 3%. Given its solid…

Amid the ongoing macroeconomic and geopolitical issues, the stock market has faced wild swings this year. As the sky-high inflation and the Fed’s aggressive rate hikes continue to heighten recessionary fears, Wall Street darlings Microsoft (MSFT), Pfizer (PFE), and Coca-Cola (KO), which have a solid dividend-paying record, might be ideal…